Hemostemix (HEM) Stock Statistics & Valuation Metrics

Hemostemix has a market cap or net worth of C$12.86M. The enterprise value is C$14.54M.

Hemostemix has 197,786,450 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hemostemix’s return on equity (ROE) is 0.95 and return on invested capital (ROIC) is 637.89%.

The current PE Ratio of Hemostemix is ―. Hemostemix’s PEG ratio is -0.66.

In the last 12 months, Hemostemix had revenue of 0.00 and earned -4.71M in profits. Earnings per share was -0.03.

In the last 12 months, operating cash flow was -5.18M and capital expenditures 7.00, giving a free cash flow of -5.18M billion.

Hemostemix pays an annual dividend of ―, resulting in a dividend yield of ―

Hemostemix upcoming earnings date is May 28, 2026, TBA (Confirmed).

Hemostemix as a current ratio of 0.49, with Debt / Equity ratio of -99.52%

In the past 12 months, Hemostemix has paid 0.00 in taxes.

Hemostemix EV to EBITDA ratio is -3.13, with an EV/FCF ratio of -3.89.

Hemostemix has C$1.30M in cash and marketable securities with C$3.44M in debt, giving a net cash position of -C$2.14M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Hemostemix is ―, which is 11.43% higher than the current price. The consensus rating is ―